Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cheap Anti-Cancer Drug is Effective in Treating Most Common Cause of Blindness in Older Adults

Published: Friday, July 19, 2013
Last Updated: Friday, July 19, 2013
Bookmark and Share
An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.

The results of a two-year trial led by Queen’s scientist, Professor Usha Chakravarthy and published in The Lancet today (Friday 19 July), show that two drug treatments Lucentis and Avastin are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD).

Wet AMD is a common cause of sight loss in older people with at least 23,000 older people diagnosed with the condition in the UK each year.  Without treatment two thirds of people with this condition will experience severe loss of sight within two years of being diagnosed.

Lucentis, the drug most commonly used in the UK at present to treat wet AMD, costs about £700 per injection and Avastin costs about £60 per injection.  The NHS could save £84.5 million annually based on injecting 17,295 eyes each year by switching from Lucentis to Avastin.  Avastin is already used to treat wet AMD in some parts of the UK and extensively elsewhere in the world and also for other eye conditions.

Over the past five years, a team of scientists and eye specialists from 23 hospitals and UK universities, including Queen’s University Belfast, University of Bristol, University of Liverpool, University of Oxford and University of Southampton, have investigated whether Lucentis and Avastin and the way they are given are equally effective and safe.

610 people with wet AMD entered a two-year trial known as IVAN which is one of the largest ever carried out in the field of eye disease in the UK. Patients received injections of the drug into the affected eye every month for the first three months.  Patients were then subdivided to receive the injections at every visit (monthly group) or only if the specialist decided there was persistent disease activity (as needed group).

The IVAN study’s two year results show that sight was equally well preserved with either of the two drugs.  Giving the treatment regularly every month, resulted in slightly better levels of sight which was detected through testing of near visual acuity and contrast sensitivity.  The ‘as needed’ group received on average 13 injections over the two year period compared to 23 for the monthly treatment group.  However, continuous treatment caused a higher proportion of eyes to develop a condition known as geographic atrophy which is a thinning of the retina and its blood supply.

Professor Usha Chakravarthy of Queen’s University Belfast’s Centre for Vision and Vascular Science, who led the research study team, said: “The IVAN results at the end of year two show that Lucentis and Avastin have similar functional effectiveness regardless of the drug received.  With respect to monthly versus as needed treatment, while there was marginally better eyesight in the former, the development of atrophy is a matter of concern in the longer term.”

Professor Barnaby Reeves and Dr Chris Rogers, Co-Directors of the Bristol Clinical Trials Evaluation Unit based at the University of Bristol, added: “The Bristol Clinical Trials Evaluation Unit (CTEU) is proud to have collaborated on this ground-breaking study.  The 610 patients on the trial made over 12,000 visits during the two-year study.

“About half of the sites had not previously taken part in such a trial and the high quality of the data is a credit both to them and to the CTEU staff, who provided the robust comprehensive clinical trial infrastructure required to deliver the trial successfully.”

The IVAN study was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme.   The Belfast Health and Social Care Trust sponsored the clinical trial. Professor Ian Young, Director of Research and Development at the Trust, said: “The findings of the IVAN study will be of great importance for the management of patients with AMD throughout the world.  Research to improve patient care is a key aspect of the work of Belfast Trust, and we are committed to sponsoring and leading important clinical trials of this kind which allow our patients early access to new treatments.”

Bernadette Hannigan, Director of Research & Development at the Department of Health, Social Services and Public Safety, who supported the trial, said: “With increasing life expectancy and a growing proportion of older people in the population, slowing the progress of conditions like AMD is key to maintaining their independence.  The IVAN trial is an example of research led from Northern Ireland with international significance - the findings have the potential to influence how AMD is managed in the future.”

The IVAN study also monitored the drugs for serious adverse events which included death, heart attacks, strokes, and any other event that was life threatening, disabling or resulted in hospitalisation.  These were similar for the two drugs.  However, deaths occurred less frequently in the group that received monthly treatment, although there were fewer deaths overall among people taking part in the trial than were expected based on their age and gender and national death rates.  When these safety results were combined with those of a similar study called the CATT trial which was performed in the USA, the resultant findings continued to indicate fewer deaths when treatment was given monthly.

The researchers state that their findings will be of relevance to the next round of technology appraisals by the National Institute for Health and Care Excellence and could lead to important changes to the way wet AMD is treated.  In the meantime, for an older person starting a course of Lucentis or Avastin, it will be important to explain the trade-off between the number of injections, and the chances of developing geographic atrophy and dying in two years.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gene Variation Identified for Teen Binge-Eating
Researchers have identified a gene variant which can lead to teenage binge eating, they hope that their work will inform the development of future preventative measures.
Wednesday, July 22, 2015
What Causes Immune Cell Migration To Wounds
Study shows triggers which lead immune cells to react and respond to wounded sites.
Friday, May 29, 2015
Fighting Prostate Cancer with a Tomato-Rich Diet
New research suggests that men who eat over 10 portions of tomatoes a week have an 18% lower risk of developing prostate cancer.
Thursday, August 28, 2014
Breakthrough Shows How DNA is ‘Edited’ to Correct Genetic Diseases
An international team of scientists has made a major step forward in our understanding of how enzymes 'edit' genes, paving the way for correcting genetic diseases in patients.
Wednesday, May 28, 2014
Deciphering the Role of Fat Stem Cells in Obesity and Diabetes
New study will examine stem cells to pinpoint how excess fat is stored, potentially paving the way for new treatments to combat obesity-linked diseases.
Wednesday, May 21, 2014
Molecular Biology Mystery Unravelled
Machinery responsible for the entry of proteins into cell membranes.
Saturday, February 22, 2014
Beauty and the Lab: Scientists Reveal the Art of Science
From a heart-shaped cell nucleus to a 3D molecular syringe, creative scientists have revealed the beauty found in complex and technical research.
Monday, December 16, 2013
New Swine Influenza Project to Better Understand Virus Transmission
The Pirbright Institute in Surrey has been awarded £4.4 million to work with researchers from universities on a long-term study on the transmission of swine influenza.
Friday, December 13, 2013
Global Carbon Dioxide Emissions to Reach 36 Billion Tonnes in 2013
Global emissions of carbon dioxide from the combustion of fossil fuels will reach 36 billion tonnes for the year 2013 – a level unprecedented in human history.
Tuesday, November 26, 2013
Human Neural Stem Cells Could Meet the Clinical Problem of Critical Limb Ischemia
New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels.
Monday, November 25, 2013
Bristol Spearheads UK’s Role in €4 Million Synthetic Biology Project
The University of Bristol has been awarded a share of a €4million (£3.3million) European Union grant to improve public awareness of synthetic biology.
Tuesday, November 19, 2013
North Atlantic Atmospheric Circulation Increases Mountainous Weather Systems and River Flow in Upland Britain
The North Atlantic Oscillation (NAO) is the most important type of climatic variability in the northern hemisphere.
Friday, August 09, 2013
New Findings Could Influence the Development of Therapies to Treat Dengue Disease
New research into the fight against Dengue may influence the development of anti-viral therapies that are effective against all four types of the virus.
Monday, August 05, 2013
Genome of 700,000-Year-Old Horse Sequenced
The oldest genome so far from a prehistoric creature has been sequenced by an international team.
Thursday, June 27, 2013
Top Honours for University’s Environmental Efforts
The University of Bristol’s efforts to be environmentally friendly and ethical are first class, according to a new league table.
Wednesday, June 12, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!